## JC20 Recoperation 0 5 OCT 2003

#### IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No.	:	PCT/EP2004/002352

International Filing Date : March 8, 2004

Priority Date(s) Claimed : April 5, 2003

Applicant(s) (DO/EO/US) : Oliver SCHADT et al.

Title: PYRAZOLE COMPOUNDS

### INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

### Timing and Fees

$\boxtimes$	Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:					
		within three months of the filing date of a national application other than a CPA under § 1.53(d);				
		within three months of the actual filing date of the national phase of a PCT application; OR				
	$\boxtimes$	before the mailing of a first substantive office action (including after filing of an RCE).				
		37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods ted in 37 C.F.R. § 1.97(b), but before the mailing date of:				
		a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and				

		is acco	ompanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:
		a final	action under 37 C.F.R. § 1.113;
		termin	nation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
		OR a	notice of allowance under 37 C.F.R. § 1.311;
	AND	is filed	on or before payment of the issue fee; AND is accompanied by:
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. § 1.17(p).
Stater	nents U	nder 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cited	Materia	<u>ıls</u>	
		ancest	s of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).
	$\boxtimes$	-	s of materials listed but not attached were cited in an international search dated <u>July 23, 2004</u> .
		Not re	quired by 37 CFR § 1.98.
		Copie	s of the materials listed are attached (except for the foregoing).

Non-	<u>English</u>	Language References
		An English-language search report or equivalent paper from a foreign paten office is provided indicating the relevance of the cited reference(s).
	$\boxtimes$	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
		<ul> <li>X = document of particular relevance when it is taken alone</li> <li>Y = document of particular relevance when it is combined with another such document</li> </ul>
		A = document defining the general state of the art O = non-written disclosure P = intercalated document
		T = document cited to understand the theory or principle underlying the invention
		E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date
		D = cited in the application
		L = cited for another reason & = publication of member of same patent family
	$\boxtimes$	Translation of other relevant information on foreign search report
		In the search report, "Seite" means page, "Seiten" means pages, "Verbindungen der Formel" means Figure of formula, "Beispele" means examples, and "das ganze Dokument" means the entire document, "Spalte" means column, "Zeile" means line, "Abbildungen" means claims, "Anspruch" means example, "Zusammenfassung" means summary, and "Tabelle" means table, and "Tabellen" means tables "in der Anmeldung erwaehnt" means cited in the application, "Schema" means scheme, "und" means and, "Absatz" means break, "Abildung" means figure.
Other	r Inform	<u>ation</u>
<u>Payn</u>	nent of F	ees Due (If Any):
	A che	ck for \$ covering the fee identified above is attached.
	Please	e charge to Deposit Account No. 13-3402 \$ for the fee identified above.

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit

Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-3075

Date: October 5, 2005

AJZ:aap

K:\Merck\3000 - 3999\3075\Information Disclosure Statement.doc

## JC20 Rec'd PET/PTO 0 5 OCT 2005

Please type a plus sign (+) inside this box

of

Sheet

PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

**MERCK-3075** 

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Application Number

Uses gland

October 5, 2005

STATEMENT BY APPLICANT

First Named Inventor

Group Art Unit

Unassigned

(use as many sheets as necessary)

Unassigned

Examiner Name

Unassigned

Attorney Docket Number

	U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No.1	U.S. Patent Document  Kind Code <sup>2</sup> Number (if known)		Kind Code <sup>2</sup>	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document  MM-DD-YYYY	
/N.J./	1	2004034083	(ii kiiowii)	or cited Document	February 19,2004		
			-				
					-		
				· · · · · · · · · · · · · · · · · · ·			

	FOREIGN PATENT DOCUMENTS							
		Foreign Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant		
Examiner Initials*	Cite No.1	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	т•
/N.J./	2	wo	03088958		Maziasz Timothy J	October 30, 2003		Equv to cite 1
			<del>0132626</del>		- Gester-Leremie-Mery-	May-19-2001	000000000000000000000000000000000000000	
			······································			•		
	-			-				
					-			

Examiner Signature	/Noble Jarrell/	Date Considered	12/27/2007

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

# JC20 Recaperato 0 5 Oct 2003

Please type a plus sign (+) inside this box	→[	+
---	----	---

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known				
INITO		DIOO	LOCUEE	Application Number	Complete if Known Uras gree 51905			
	RMATION			Filing Date	October 5, 2005			
STATEMENT BY APPLICANT				First Named Inventor	Oliver SCHADT et al.			
				Group Art Unit	Unassigned			
(use as many sheets as necessary)				Examiner Name	Unassigned			
Sheet	2	Of	2	Attorney Docket Number	MERCK-3075	7		

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
	4	DATABASE BEILSTEIN 'ONLINE! BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; JUNE 27, 1988, XP002283830.	*************				
		FRANKFURT-MAIN, DE; JUNE 27, 1988, XP002283830.					
			-				
•							
<u>_</u>							

		•	
Examiner	/Noble Jarrell/	Date	10/07/0007
Signature		Considered	12/27/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.